Pharmaceuticals

JZT released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 973.24 M, actual EPS CNY 0.1949

JZT to Release FY2026 Q1 Earnings on April 23 After-Market (BJT)

JZT released FY2025 Annual Earnings on March 26 After-Market (BJT), Actual Revenue: CNY 2.229 B, Actual EPS: CNY 0.263

JZT released FY2025 Q4 earnings on March 26 After-Market (BJT), actual revenue CNY 601.8 M, actual EPS CNY 0.0838

JZT to Release FY2025 Earnings on March 27 After-Market (BJT)

JZT released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 362.94 M, actual EPS CNY 0.0091

JZT released FY2025 9 Months Earnings on October 29 After-Market (BJT), Actual Revenue CNY 1.627 B, Actual EPS CNY 0.179

JZT FY2025 Q3 Earnings Release on October 30, After-Market (BJT)

JZT released FY2025 Q2 earnings on August 20 After-Market (BJT), actual revenue CNY 458.84 M, actual EPS CNY 0.0321

JZT released FY2025 Semi-Annual Earnings on August 20 After-Market (BJT), actual revenue CNY 1.265 B, actual EPS CNY 0.1699

JZT to Release FY2025 Semi-Annual Earnings on August 21, 2025 (BJT)

Nine Treasure Hall Obtains Patent for Establishing Fingerprint Map Method of Danxiquan Granules

Nine Treasure Hall Holds Shareholders' Meeting to Elect New Non-Executive Directors and New Chairman

Jiuzhitang Stock Rises 21% in Two Consecutive Days

Jiuzhitang Conducts a Block Trade

Nine Treasure Hall Board Members Resign and Nominate New Directors

Nine Treasure Hall's 5%+ shareholder Li Zhen Guo's share pledge and release

Nine Treasure Hall's Yiboshi Launches Phase II Clinical Trial for YB211 Project

Nine Treasure Hall Establishes Herbal Non-Tea Business Operation Management Company

ST Jiuzhitang to Delist Risk Warning and Resume Trading

000989

JZT announced that the revenue for the third quarter was 363 million yuan, a year-on-year decrease of 5.51%; the net profit was 7.758 million yuan, a year-on-year decrease of 78.30%. The revenue for the first three quarters was 1.627 billion yuan, a year-on-year decrease of 21.13%; the net profit was 152 million yuan, a year-on-year decrease of 36.94%

Zhitong

JZT: Net profit in the third quarter was 7.758 million yuan, a decrease of 78.30%

JZT released its semi-annual report for 2025, reporting operating income of 1.265 billion yuan, a year-on-year decrease of 24.71%; net profit attributable to shareholders of the parent company was 144 million yuan, a year-on-year decrease of 29.71%; net profit excluding non-recurring gains and losses was 136 million yuan, a year-on-year decrease of 28.45%; basic earnings per share were 0.1699 yuan

JZT released its performance for the first half of the year, with a net profit attributable to the parent company of 144 million yuan, a year-on-year decrease of 29.71%

688302

688331

09995

The concept of innovative drugs has rebounded, with JZT hitting the daily limit, Hinova, RemeGen, and Shenzhou Cell rising over 10%, while Fuyuan Pharmaceutical, Kangchen Pharmaceutical, Guangshengtang, and Nuo Cheng Jianhua are among the top gainers

Hinova

RemeGen

REMEGEN

The concept of innovative drugs fluctuates and rebounds, JZT hits the limit up

JZT's stock hit the upper limit and achieved a 2-day consecutive increase, with a cumulative rise of 21.0%

688136

600276

301257

688202

Innovative drug concept stocks rebound after hitting bottom, JZT reaches the daily limit, ClinPlus rises over 10%, Medicilon, SDKX, and Hengrui Pharma all rise

SDKX

Hengrui Pharma

ClinPlus

Medicilon

Innovative drug concept stocks rebound after hitting bottom, JZT reaches the daily limit

603716

688553

The innovative drug concept fluctuated and rebounded during the day, with the CXO sector leading the gains. ClinPlus rose over 10%, while Medicilon, JZT, Thalys, HUIYU PHARMACEUTICAL, and Shanghai Yizhong all rose over 6%

Thalys

HUIYU PHARMACEUTICAL

The concept of innovative drugs fluctuates and rebounds, ClinPlus rises over 10%

On July 3rd, JZT had a block trade of 10 million shares, with a transaction amount of 95.6 million yuan, accounting for 15.59% of the total transaction amount that day. The transaction price was 9.56 yuan, a discount of 4.02% compared to the market closing price of 9.96 yuan

JZT conducted a block trade today at a discount, with 10 million shares traded and a transaction amount of 95.6 million yuan

JZT announced that Chairman Sun Guangyuan resigned due to work changes, and Lv Ming and Bo Jinfeng also resigned from their director positions. After their resignations, they will no longer hold any positions in the company or its subsidiaries. The resignations will not affect the legal number of board members, and three non-independent directors need to be re-elected, with Wang Lifeng, Wu Qiang, and Yu Zhongfei nominated as candidates

JZT: Sun Guangyuan resigned as chairman due to job changes

300003

The three major stock indices closed higher, with the innovative drug sector performing prominently, as Lepu Medical and JZT hit the daily limit. The beer concept and beauty care sectors also saw significant increases, with Shuiyang Co., Ltd. leading the gains. In contrast, the logistics and airport shipping sectors generally declined. Overall, nearly 4,000 stocks rose, indicating a broad market rally

Lepu Medical

CHINA EAST AIR

Haoyue Care

Guilin Sanjin

WBDE

Jiamei Packaging

NBOND

XNWL

LEHUI INTERNATIONAL

Closing Review: All three major indices closed higher, innovative drugs usher in a major breakthrough

002612

002762

600223

000661

300740

The medical beauty concept fluctuated and rose, with SYG increasing by over 17%, JZT and JFLB hitting the limit up, and Freda, CCHT, LANCY, and others leading in gains

LANCY

JFLB

Freda

CCHT

The medical beauty concept fluctuates and rises, with SYG increasing by over 17%

JZT(000989.SZ)